CIPLA LTD vs POLY MEDICURE LIMITED
A side-by-side comparison of CIPLA LTD (CIPLA) and POLY MEDICURE LIMITED (POLYMED) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads CIPLA vs POLYMED on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation40
- Profitability22
- Growth02
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
CIPLA takes 4/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
EvenHow efficiently each company turns capital and sales into profit. Higher is better.
Growth
POLYMED takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
CIPLA takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
- + ["Company has delivered good profit growth of 19.4% CAGR over last 5 years"]
- − ["Company has a low return on equity of 12.6% over last 3 years.", "Debtor days have increased from 83.9 to 103 days."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.